New research suggests that popular diabetes and weight-loss drugs like Ozempic and Wegovy may be associated with a small increase in the risk of osteoporosis and gout. The findings, presented at a recent medical conference, highlight the need for doctors to monitor patients closely while they are on these medications.
Study Findings: A Small but Notable Increase
Researchers analyzed medical records of over 146,000 adults with both type 2 diabetes and obesity over a five-year period. Those taking GLP-1 medications (including semaglutide and liraglutide) had a roughly 29% higher risk of developing osteoporosis compared to those not on the drugs. Gout cases were also slightly more frequent in the GLP-1 group, with a 12% increase in incidence.
While the absolute risk differences are small, the study raises concerns about potential long-term effects on bone and joint health. Osteomalacia, a condition causing bone softening, was also observed more often in GLP-1 users, though it remained rare.
Why This Matters: Weight Loss and Metabolic Changes
The connection between GLP-1 drugs and bone/joint health likely stems from multiple factors. These medications work by suppressing appetite and promoting weight loss, which can alter nutrient absorption and reduce intake of bone-essential vitamins like calcium and vitamin D.
Rapid weight loss, similar to that seen with bariatric surgery, can also lower bone density over time. The body enters a catabolic state during weight loss, breaking down tissue for energy and releasing uric acid as a byproduct—potentially triggering gout attacks in vulnerable individuals.
What Healthcare Providers Should Do
The study emphasizes that GLP-1 drugs remain valuable tools for managing diabetes and obesity, but close patient monitoring is critical. Doctors should regularly assess nutrition, bone density, and overall metabolic health in those taking these medications.
Key Recommendations:
- Regular bone density screenings.
- Adequate calcium and vitamin D intake.
- Strength training to build muscle and bone.
- Comprehensive blood tests beyond standard diabetes markers.
The findings don’t prove causation, but they underscore the importance of holistic health management alongside GLP-1 therapy. The study does not apply to people using GLP-1 drugs solely for weight loss.
Conclusion
The new research suggests a modest association between GLP-1 drugs and increased risks of osteoporosis and gout, but these medications remain valuable in treating diabetes and obesity. Vigilant monitoring by healthcare providers, combined with lifestyle adjustments, can mitigate these risks and ensure patients benefit fully from treatment.
